Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue (Q38157807)

29 August 2017

title

Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue (English)

1 reference

29 August 2017

0 references

0 references

0 references

Scott B Halstead

1 reference

29 August 2017

language of work or name

1 reference

12 July 2017

1 reference

Lancet Infectious Diseases

29 August 2017

published in

1 reference

on focus list of Wikimedia project

29 August 2017

WikiProject Zika Corpus

0 references

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Zika Virus in the Americas — Yet Another Arbovirus Threat

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Considerations for Developing a Zika Virus Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Fast-Track Zika Vaccine Development — Is It Possible?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Vaccine Development for Zika Virus-Timelines and Strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Vaccination strategies against Zika virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Rapid development of a DNA vaccine for Zika virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Vaccine protection against Zika virus from Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Modified mRNA Vaccines Protect against Zika Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Zika virus-like particle (VLP) based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

The global distribution and burden of dengue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Dengue vaccine development: a 75% solution?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Efficacy of tetravalent dengue vaccine in Thai schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

T-cell immunity to infection with dengue virus in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

A Protective Role for Dengue Virus-Specific CD8+ T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Role of humoral versus cellular responses induced by a protective dengue vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Intracellular Cytokine Production by Dengue Virus–specific T cells Correlates with Subclinical Secondary Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Efficacy of a tetravalent dengue vaccine in children in Latin America.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Research on dengue during World War II

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Reduced risk of disease during postsecondary dengue virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Identifying protective dengue vaccines: guide to mastering an empirical process

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Assessment of humoral and cell-mediated immune response to measles-mumps-rubella vaccine viruses among patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

T-cell immunity to human alphaherpesviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

The Development of Small Animal Models for Zika Virus Vaccine Efficacy Testing and Pathological Assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Zika Virus Pathogenesis and Tissue Tropism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Characterization of a Novel Murine Model to Study Zika Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Modeling Zika Virus Infection in Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

Structural basis of potent Zika–dengue virus antibody cross-neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930362-6

7 January 2021

10.1016/S1473-3099(17)30362-6

Identifiers

DOI

1 reference

29 August 2017

1 reference